Report Type: Industry Trends
Report Category: Regulatory Insights
Report Subcategory: Orphan Drug Designation
Price: 2999.00
Date: February 2022

Orphan Drug Designation (ODD): Drugs, Companies, News, Deals, Patents, Drug Sales & Forecast, Future Events, DMF, Manufacturing

Orphan Drug Designation (ODD) provides market exclusivity for the rare indication drugs. ODD criteria varies by country.

Regulatory authorities provides ODD are US FDA, Europe EMEA,Japan PMDA, China NMPA, Australia TGA, South Korea KFDA, Brazil ANVISA, Mexico COFEPRIS, France ANSM, Spain AEMPS and etc.